Therapies with EGFR and ALK tyrosine kinase inhibitors (TKI) are standard-first line treatments in EGFR-mutant and ALK-rearranged NSCLC patients, respectively (10, 11). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.